Search

Contributor:

and David S. Boyer, MD

AAO 2021 Late Breakers: DAVIO and NORSE-2

The Multifactorial Pathophysiology of DME

The Multifactorial Pathophysiology of DME

David Boyer MD

Update on Encapsulated Cell Technology

Update on Encapsulated Cell Technology

David Boyer MD, Jonathan L. Prenner, MD

OCT-A May Provide Better Visualizations of Vascularized PED's in AMD patients than FA

OCT-A May Provide Better Visualizations of Vascularized PED's in AMD patients than FA

David Boyer, MD

OCT-A for Identifying CNV in Patients with Type 1 AMD and Assessing Response to anti-VEGF treatment

OCT-A for Identifying CNV in Patients with Type 1 AMD and Assessing Response to anti-VEGF treatment

David Boyer, MD

OCT-A in Context: Why OCT-A Must Be Evaluated Together With OCT B-Scan

OCT-A in Context: Why OCT-A Must Be Evaluated Together With OCT B-Scan

David Boyer, MD

Take-Home Points for APL-2

Take-Home Points for APL-2

David S. Boyer, MD

DEL MAR: Phase 2, Stage 2

DEL MAR: Phase 2, Stage 2

David S. Boyer, MD

An Update on Suprachoroidal RGX-314

An Update on Suprachoroidal RGX-314

David S. Boyer, MD

Innovations in Dry AMD Treatment: Photobiomodulation

Innovations in Dry AMD Treatment: Photobiomodulation

I. Paul Singh, MD; and David S. Boyer, MD

Central Serous Retinopathy Pearls

Central Serous Retinopathy Pearls

David S. Boyer, MD

LIGHTSITE III: Month 24 Clinical Trial Results in Dry AMD Patients

LIGHTSITE III: Month 24 Clinical Trial Results in Dry AMD Patients

David S. Boyer, MD; and Marion R. Munk, MD, PhD

AAO 2021 Late Breakers: DAVIO and NORSE-2

David Boyer, MD; and Firas Rahhal, MD